Overview of the Clinical Trial Process

Mary Long caught up with Motley Fool Contributor Keith Speights to check in on the psychedelic industry. They discuss:  

- Advice to investors looking at a highly speculative industry.

- The cash and regulatory questions for these companies. 

- Key differences between the cannabis market and psychedelic stocks.

- The challenges of doing a double-blind test on psychedelic compounds.

Companies discussed: CMPS, CYBN, ATAI

Host: Mary Long

Guest: Keith Speights

Producer: Ricky Mulvey 

Engineers: Rick Engdahl, Desireé Jones

Learn more about your ad choices. Visit megaphone.fm/adchoices